Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)

NANot yet recruitingINTERVENTIONAL
Enrollment

1,170

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2027

Conditions
Chronic Kidney Disease(CKD)Type 2 DMType 2 Diabetes Mellitus (T2DM)
Interventions
OTHER

(IRIS-CKD Management Program): Education

Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their Primary Care Provider (PCP). At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period.

OTHER

(IRIS-CKD Management Program): GDMT

Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their PCP. At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period. Plus, receive guided care by APP.

Trial Locations (1)

27707

Duke University, Durham

Sponsors

Lead Sponsor

Collaborators (2)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

Duke University

OTHER